3. New Animal Model Of Catheter-Selective Middle Cerebral Artery Thrombo-Occlusive Stroke: Demonstration Of Rapid Reperfusion By Local Plasmin Infusion
(Abstract # P-S-400):
-- Preliminary data utilizing a clinically-relevant animal model for human ischemic stroke will help guide clinical protocol development in this area.
4. Importance of Fibrin Binding for Therapeutic Efficacy of Direct Thrombolytics
(Abstract # P-S-383):
-- Valery Novokhatny, Ph.D., Research Fellow, Talecris Biotherapeutics, presented the company's ongoing biotechnology research efforts to develop a recombinantly-modified deletion mutant of plasmin, (delta) plasmin, ((delta)Pm), TAL-6003, working to optimize fibrin binding and fibrinolytic potency.
"As Talecris continues to develop Plasmin, we discover more about the diverse potential uses for this unique thrombolytic," said Alberto Martinez, M.D., President and COO of Talecris Biotherapeutics. "Plasmin represents another example of Talecris' R&D efforts to continue discovering and developing therapies that address unmet clinical needs."
Satellite Symposium: "Potential for Better Thrombolytic Therapy: Is Plasmin the Answer?"
Talecris also hosted a Satellite Symposium breakfast meeting at
ISTH. "The symposium brings together recognized experts to discuss
where we expect the next generation of thrombolytics to take us in
terms of improved safety and effectiveness," said Program Chair of
the Symposium, Gilbert C. White, M.D., Blood Research Institute in
Milwaukee, Wisconsin. "Certainly Plasmin appears to have unique
properties that could produc